LNTH vs RMD vs BWXT vs EXAS vs ROIV

For growth investors, BWX Technologies, Inc.

(BWXT) is the stronger pick with 18. 3% revenue growth year-over-year, versus -11. 2% for Roivant Sciences Ltd. (ROIV). ResMed Inc. (RMD) offers the better valuation at 21. 8x trailing P/E (18. 8x forward), making it the more compelling value choice. Analysts rate Lantheus Holdings, Inc. (LNTH) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ResMed Inc.

(RMD) is the cheapest at 21. 8x versus BWX Technologies, Inc. at 58. 4x. On forward P/E, Lantheus Holdings, Inc. is actually cheaper at 17. 5x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus BWX Technologies, Inc. 's 10. 61x — a reasonable growth-adjusted valuation.

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to +0. 4% for Exact Sciences Corporation (EXAS). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus ROIV's +171. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus BWX Technologies, Inc. 's 1. 60β — meaning BWXT is approximately 1229% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 163% for BWX Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), BWX Technologies, Inc.

(BWXT) is pulling ahead at 18. 3% versus -11. 2% for Roivant Sciences Ltd. (ROIV). On earnings-per-share growth, the picture is similar: Exact Sciences Corporation grew EPS 80. 3% year-over-year, compared to -104. 6% for Roivant Sciences Ltd.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ResMed Inc.

(RMD) is the more profitable company, earning 27. 2% net margin versus -592. 0% for Roivant Sciences Ltd. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus -34. 5% for ROIV. At the gross margin level — before operating expenses — ROIV leads at 96. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus BWX Technologies, Inc. 's 10. 61x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Lantheus Holdings, Inc. (LNTH) trades at 17. 5x forward P/E versus 582. 8x for Exact Sciences Corporation — 565. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RMD: 35. 9% to $281. 29.

In this comparison, RMD (1.

0% yield), BWXT (0. 5% yield) pay a dividend. LNTH, EXAS, ROIV do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). BWX Technologies, Inc. (BWXT) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, BWXT: +551. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LNTH (Healthcare) and RMD (Healthcare) and BWXT (Industrials) and EXAS (Healthcare) and ROIV (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LNTH is a small-cap quality compounder stock; RMD is a mid-cap quality compounder stock; BWXT is a mid-cap high-growth stock; EXAS is a mid-cap high-growth stock; ROIV is a mid-cap quality compounder stock. RMD pays a dividend while LNTH, BWXT, EXAS, ROIV do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.